Stocks that moved the day before part 2, such as Takakyu, Dai-Do, and Played, etc.
Stock Name <Code> 11th Closing Price ⇒ Day-Over-Day Comparison M&A Kensetsu <9552> 3705 -60 Continuing concern over some media articles. Appier Group <4180> 1188 -64 Pressured by the overall trend of small and medium-sized growth stocks selling off. Japan Investment Advisor <7172> 1647 -59 Development of profit-taking selling is being gathered in the high-priced range. Sansan <4443> 1730 -53, although earnings reports are expected to be released on the 11th. Zensho HD <755>
Emerging market stock digest: Shirugaku hits a new high this year, Progrit skyrockets.
<3063> jGroup rose 14 points to 684. After the trading session on the 10th, the company announced its financial results for the first quarter of the 2025 fiscal year. Revenue increased by 5.6% YoY to 2.717 billion yen, and operating profit reached a profit of 75 million yen (compared to a loss of 7 million yen in the same period last year), which was well received by the market. Along with the closure of two directly managed stores, the company continues to focus on optimizing personnel allocation, improving productivity, reducing headquarters expenses, and working on repair and renovation of existing stores and developing new business models.
Active and newly listed stocks during the morning session.
*MonotaRO<3064> 2099.5 +255.56. Positive view on monthly trends for the month. *Treasure Factory<3093> 2003 +185. Performance forecast revised upward due to better than expected results in the first quarter. *AZ Maruwa HD<9090> 1200 +86. It is covered by some media as a candidate for contrarian stockpicking. *FP Partner<7388> 3225 +180. Continue to view the good performance of new life insurance contracts in June as a material. *SG Holdings.
Hot stocks digest (morning session): dai, shift, MRO, Torefac, etc.
Saizeriya<7581>: 5,460 yen (-290 yen), a large decline. The company announced its third-quarter results the previous day, with cumulative operating profit reaching 10.1 billion yen, 2.8 times higher than the same period last year. The earnings report exceeded expectations. The annual dividend was also increased from the previous plan of 18 yen to 25 yen. However, it seems that the announcement of the abolition of the shareholder benefit system from the end of August 24 has become a selling point. It seems that they have considered the perspective of fair profit return to shareholders. Until now, the
Three points to watch in the afternoon session - with high-tech stocks rising, the price temporarily rose to the 42,400 yen level.
In the afternoon trading on the 11th, we want to focus on the following three points. ・The Nikkei average has risen for three consecutive days, rising to the 42,400 yen range at one point due to the high-tech stock surge. ・The dollar-yen exchange rate is strong, and Japanese stocks continue to rise. ・The top contributors to the price increase are First Retail<9983> and second is Tokyo Electron<8035>. ■ The Nikkei average has risen for three consecutive days, rising to the 42,400 yen range at one point. The Nikkei average has risen for three consecutive days, up 347.85 yen (0.83%) from the previous day to 42,179.84 yen (estimated volume of about 910 million10 thousand shares).
Stocks that hit the daily limit up or down in the morning session.
Stop high: <4169> ENECHANGE <4890> Tsubota Lab <7138> TORICO <7776> CellSeed <8166> Takakyu. Stop low. * Includes temporary stop high and low (indication value).
Pingtian Lab - Year-to-date high update, clinical results for Parkinson's disease and depression are favorable.
At the beginning of the year, it reached a new high and temporarily hit the limit up. On the 9th, the results of specific clinical studies evaluating the safety and efficacy of TLG-005 (violet light glasses) for "Parkinson's disease" and evaluating the safety and efficacy of TLG-005 for "depression" were announced, and although it reached the limit up on the 10th, it continues to be considered as a material. No serious adverse events were observed in both studies, and results demonstrating efficacy were obtained. Based on these results
The TOPIX 250 index on the Tokyo Stock Exchange's Growth Market continued to decline, while the main board market remained dominant.
Tokyo Stock Exchange Growth Market Index: 843.18, -4.03 / Volume: 0.2 billion 7.86 million shares / Transaction Value: 160.7 billion yen. Tokyo Stock Exchange Growth Market 250 Index: 654.51, -3.42 / Volume: 0.1 billion 17.04 million shares / Transaction value: 123.5 billion yen. Today's Growth Market saw a continuation of the decline in both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index. The number of rising stocks was 182, falling stocks were 365, and unchanged were 31. The US stock market on the 9th was mixed. The Dow Jones Industrial Average fell by 52.82 dollars (-0.
Pingtian Lab -- Interim report on specific clinical study results of TLG-005 targeting depression.
On the 9th, Tingda Lab<4890> announced the interim report evaluating the safety and effectiveness of TLG-005 (violet light glasses) for depression conducted by the company. This study, conducted in August 2021 with the cooperation of Keio University School of Medicine, Department of Psychiatry and Neurology, Professor Kado Noda, and others, registered 70 patients diagnosed with major depressive disorder, all of whom were irradiated with test equipment (violet light irradiation) and control equipment. The evaluation of the main evaluation items related to the equipment.
Emerging markets stock digest: Aizu rebounds significantly, NPC temporarily hits the limit.
<4890> Tsuburata Lab 474 +80 stop high. They announced the interim report of the specific clinical study evaluating the safety and effectiveness of TLG-005 (violet light glasses) for Parkinson's disease, confirming the safety of the device and obtaining results suggesting the effectiveness for some symptoms of Parkinson's disease. Additionally, in the interim report of the specific clinical study evaluating the safety and effectiveness of TLG-005 for depression, serious adverse events were not observed, and results were obtained for major depressive disorder.
Active and newly established stocks in the afternoon session.
*AOI Electronics <6832> increased by 2942 points (+226). Sharp establishes a production line for cutting-edge semiconductor panel packages at its Mie factory. *Cojin Bio <177A> increased by 2009 points (+157). It releases a serum-free medium, "KBM EV Pure," for exosome production. *Cyfuse <4892> increased by 789 points (+56). It has developed a new freezing technology that is expected to be practical for 3D cell products with Iwatani Industries <8088>. *Tsubota Lab <4890> increased by 474 points (+80). It...
Stocks hitting the upper or lower price limit in the afternoon session.
Stop high <2164>, regional newspaper company <2687>, sea V.S. bay area <3055>, Hokuyaku Takayama Holdings <4169>, ENECHANGE <4288>, Azujent <4424>, Amazia <4735>, Kyoshin <4890>, Tsubota Lab <4892>, Cyfuse <4935>, Libreita <5957>, Nihon Seiko <6255>, NPC <7776>, Cell seed Stop loss * including temporary stop high and low (indication value).
Stop buying sentiment for Tsubota Lab, indicating the effectiveness of TLG-005 in a specific clinical study targeting Parkinson's and depression.
There is a buying indication for the stock price limit. A preliminary report has been released on a specific clinical study evaluating the safety and efficacy of TLG-005 (violet light glasses) for Parkinson's disease. The safety of the device has been confirmed, and results suggesting effectiveness for some symptoms of Parkinson's disease have been obtained. In addition, a preliminary report on a specific clinical study evaluating the safety and efficacy of TLG-005 for depression also showed results indicating effectiveness for major depressive disorder without any serious adverse events.
A stable and calm external environment brings a sense of security.
[Emerging Markets individual stock strategy] Today's emerging markets are expected to show a solid development. In the US stock market on the 9th yesterday, the Dow average plummeted by 52.82 dollars (-0.13%) to 39,291.97 dollars, continuing the downtrend. Federal Reserve Chairman Powell mentioned in congressional testimony that the recent data shows a slowdown in the economy and labor market, which weighed on stock prices. On the other hand, the buying of high-tech stocks continues, and the Nasdaq Composite Index is steadily trending, setting a new all-time high for the 6th consecutive day. Now,
WACUL, Tsubota Lab, and others [Emerging Markets Press Release]
Acquisition of own shares for LAHD <2986> has ended. <4173> WACUL has signed a capital business alliance agreement with 100 to handle the introduction of HubSpot/accelerate DX utilization support with HubSpot. <4890> Tsubota Lab has reported specific clinical research results for TLG-005 targeting depression and Parkinson's disease.
Pitanda Lab has established an office in Eye Valley, Wenzhou City, Zhejiang Province, China.
Pitanda Lab <4890> announced on the 3rd that it has opened an office in "Eye Valley" located in Wenzhou City, Zhejiang Province, China. The name is "Eye Valley Pitanda Lab Office" and the opening date is July 2, 2024. For the time being, it will be used as a base for information gathering and no staff will be sent there. The company is promoting research on myopia and dry eye, both of which have been reported in large numbers of patients in China and Asia, and has a network of numerous researchers in the region.
Tsubota Lab - Mr. Kazuo Tsubota appointed as a guest professor of ophthalmology at Wenzhou Medical University.
On the 3rd, Tsubota Lab <4890> announced that its representative, Kazuo Tsubota, had been appointed as a visiting professor in ophthalmology at Wenzhou Medical University (located in Wenzhou City, Zhejiang Province, China). The company is promoting research on myopia and dry eye, but both diseases have been reported in large numbers of patients in China and Asia. The ophthalmology department of Wenzhou Medical University has national platforms such as visual science research, ophthalmology disease clinical center, and a nationally operated "myopia diagnosis and treatment technology center" in the field of Chinese ophthalmology.
Tsubota Laboratory: Confirmatory letter.
Tsubota Laboratory: Securities Report - 12th Period (April 1, 2023 - March 31, 2024)
GoodSpeed, VirusMart, and others
<175A> Virusmart downward revision, expected operating loss for this fiscal year is -90 million yen instead of 120 million yen. <4890> Terada Lab terminates licensing contract due to the settlement of Twenty Twenty Therapeutics. <5834> SBI Leasing acquires aircraft for sales. <7676> Usami Kogyo, which oversees the management and capital of the entire Usami Uzumi Group, enters into a capital business partnership agreement and issues new shares through third-party allotment (1,764,800 shares) to Usami Kogyo.
No Data